Skip to main content
Premium Trial:

Request an Annual Quote

City of Hope, Translational Genomics Research Institute Form Personalized Medicine Alliance

NEW YORK (GenomeWeb) – City of Hope and the Translational Genomics Research Institute (TGen) announced today that they have formed a precision medicine partnership focused on translating genomic discoveries into clinical practice.

As part of the deal, TGen will become a subsidiary of City of Hope's parent organization, but will remain a non-profit headquartered in Phoenix, Arizona.

The alliance will join City of Hope's clinical expertise in bone marrow transplantation, hematologic malignancies, solid tumors, and diabetes with TGen's know-how in genomic analysis and bioinformatics for cancer drug development. The partners said they aim to develop a program — called Personalized Hope — to detect diseases sooner and improve quality of life and survival for patients, with an initial focus on immune function and the rational design of new immune interventions.

"This alliance will enable us to fully deploy genomic-enabled medicine within a modern healthcare system to create a disruptive change in the practice of medicine," TGen President Jeffrey Trent said in a statement.

"Together, City of Hope and TGen will cover the bench-to-bedside continuum," City of Hope Provost and CSO Steven Rosen added. "Our complementary strengths will propel us to the forefront of personalized medicine."